nothofagin has been researched along with Diabetes-Mellitus--Type-2* in 1 studies
1 other study(ies) available for nothofagin and Diabetes-Mellitus--Type-2
| Article | Year |
|---|---|
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
Inhibiting glucose reabsorption by sodium glucose co-transporter proteins (SGLTs) in the kidneys is a relatively new strategy for treating type 2 diabetes. Selective inhibition of SGLT2 over SGLT1 is critical for minimizing adverse side effects associated with SGLT1 inhibition. A library of C-glucosyl dihydrochalcones and their dihydrochalcone and chalcone precursors was synthesized and tested as SGLT1/SGLT2 inhibitors using a cell-based fluorescence assay of glucose uptake. The most potent inhibitors of SGLT2 (IC Topics: Chalcones; Diabetes Mellitus, Type 2; Glucosides; HEK293 Cells; Humans; Membranes, Artificial; Molecular Docking Simulation; Phosphatidylcholines; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |